A Better Flu Vaccine
by Gertrud U. Rey On June 18, 2026, the top advisory committee for the Food and Drug Administration (FDA) unanimously recommended Moderna’s new mRNA influenza vaccine, mRNA‑1010 (mFlusiva), for adults aged 50 and older. The vote marked the committee’s first review of a new vaccine application since 2023 and demonstrated strong support ahead of a …
